ESC 2016: Applying Novel Therapeutics to Improve Outcomes in Patients with Pulmonary Arterial Hypertension

http://academiccme.com/wp-content/uploads/2017/01/910663-125-X-125.jpg

Course Information

Therapautic Area: Cardiology
Format(s): Meeting Reporter
Credit(s): 0.50 AMA PRA Category 1 Credit(s)™
Activity Dates: December 29, 2016 - December 28, 2017

 

Course Description

This CME program will cover data on current and emerging therapeutic options for treating patients with pulmonary arterial hypertension (PAH) that was presented at the European Society of Cardiology 2016 Annual Congress held in Rome, Italy. The expert faculty will discuss recent clinical trial data on pulmonary arterial hypertension along with ways to integrate new information into daily practice. Clinicians will gain a better understanding of ways to improve outcomes for their patients with PAH by providing the most up-to-date care.

Target Audience

Cardiologists, primary care physicians, and other healthcare professionals who care for patients with pulmonary arterial hypertension.

Educational Objectives

Upon completion of this activity, participants will be better able to the following:

  1. Understand the application of current and emerging therapeutic options for treating pulmonary arterial hypertension
  2. Analyze data from clinical trials on pulmonary arterial hypertension therapeutics
  3. Integrate new data into clinical practice to lower risks and improve outcomes in patients with pulmonary arterial hypertension

Faculty

ioana-preston-mdIoana Preston, MD
Pulmonary Function Lab Director
Director, Pulmonary Hypertension Center
Associate Professor, Tufts University School of Medicine
Boston, MA

 

 

Financial Support

This CME activity has been supported by an independent educational grant from Actelion Pharmaceuticals US, Inc.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.


Registration



Actelion Pharmaceuticals US Inc.